Acupath Laboratories Inc. and UroGPO Announce a Partnership to Offer the URO17® Bladder Cancer Biomarker in the United States
URO17 is a non-invasive, cost-effective urine-based biomarker used in diagnosis and management of bladder cancer, the 6th most common form of cancer in the US.
- URO17 is a non-invasive, cost-effective urine-based biomarker used in diagnosis and management of bladder cancer, the 6th most common form of cancer in the US.
- Available as a Laboratory Developed Test (LDT) inthe United States, Acupath was the first lab worldwide to offer URO17 in July 2019 and has performed over 20,000 tests since that time.
- UroGPO will offer discounted reagents and information for the URO17 test to the members of their Group Purchasing Organization.
- Acupath Labs and the UroGPO network are excited to formally make URO17 available to urology practices nationwide.